Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
In this recently published phase 3 randomized controlled trial, neoadjuvant nab-paclitaxel/trastuzumab/pertuzumab x6 cycles appear to compare favorably with TCHP. Would you consider this data practice changing; if so, in which patients would you consider de-escalated therapy?
Community PollStarted
Given the HELEN-006 trial results, which patients would you consider de-escalated neoadjuvant therapy with trastuzumab/pertuzumab/nab-paclitaxel in HER2-positive breast cancer?
74 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Virginia
Answered on
The phase III HELEN-006 trial of abraxane/trastuzumab/pertuzumab (AHP) vs TCHP was first presented with positive results at SABCS 2023, then at AACR 2024, and finally published fully in January 2025 in the Lancet. To summarize the findings, the Lancet 2025 article documented that in this randomized ...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · 21st Century Oncology Jacksonville, Inc.
Answered on
Agree with considering patients with advanced age and co-morbidity while waiting for the long-term survival data.
Join for free or sign in to see the full answer